Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells

BMC Complementary and Alternative Medicine

Alok C Bharti³  Bhudev C Das¹  G Mugesh²  Arvind Pandey³  Shirish Shukla³  Saurabh Maru³  Sutapa Mahata³ 

[1]Dr. B.R Ambedkar Centre for Biomedical Research, University of Delhi (North Campus), Delhi 110007, INDIA

[2]Department of Inorganic and Physical Chemistry, Indian Institute of Science, Bangalore 560 012, INDIA

[3]Division of Molecular Oncology, Institute of Cytology and Preventive Oncology (ICMR), I-7, Sector-39, Noida 201301, INDIA

关键词: HPTLC;    NMR;    AP1;    HeLa cells;    Human Papillomavirus;    Bryophyllum pinnata;   

Others  :  1232837
DOI  :  10.1186/1472-6882-12-15

 received in 2011-11-14, accepted in 2012-03-10,  发布年份 2012

【 摘 要 】

Background

Bryophyllum pinnata (B. pinnata) is a common medicinal plant used in traditional medicine of India and of other countries for curing various infections, bowel diseases, healing wounds and other ailments. However, its anticancer properties are poorly defined. In view of broad spectrum therapeutic potential of B. pinnata we designed a study to examine anti-cancer and anti-Human Papillomavirus (HPV) activities in its leaf extracts and tried to isolate its active principle.

Methods

A chloroform extract derived from a bulk of botanically well-characterized pulverized B. pinnata leaves was separated using column chromatography with step- gradient of petroleum ether and ethyl acetate. Fractions were characterized for phyto-chemical compounds by TLC, HPTLC and NMR and Biological activity of the fractions were examined by MTT-based cell viability assay, Electrophoretic Mobility Shift Assay, Northern blotting and assay of apoptosis related proteins by immunoblotting in human cervical cancer cells.

Results

Results showed presence of growth inhibitory activity in the crude leaf extracts with IC₅₀ at 552 μg/ml which resolved to fraction F4 (Petroleum Ether: Ethyl Acetate:: 50:50) and showed IC₅₀ at 91 μg/ml. Investigations of anti-viral activity of the extract and its fraction revealed a specific anti-HPV activity on cervical cancer cells as evidenced by downregulation of constitutively active AP1 specific DNA binding activity and suppression of oncogenic c-Fos and c-Jun expression which was accompanied by inhibition of HPV18 transcription. In addition to inhibiting growth, fraction F4 strongly induced apoptosis as evidenced by an increased expression of the pro-apoptotic protein Bax, suppression of the anti-apoptotic molecules Bcl-2, and activation of caspase-3 and cleavage of PARP-1. Phytochemical analysis of fraction F4 by HPTLC and NMR indicated presence of activity that resembled Bryophyllin A.

Conclusions

Our study therefore demonstrates presence of anticancer and anti-HPV an activity in B. pinnata leaves that can be further exploited as a potential anticancer, anti-HPV therapeutic for treatment of HPV infection and cervical cancer.

【 授权许可】

   
2012 Mahata et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Tan G, Gyllenhaal C, Soejarto DD: Biodiversity as a source of anticancer drugs. Curr Drug Targets 2006, 7(3):265-277.
• [2]Akinpelu DA: Antimicrobial activity of Bryophyllum pinnatum leaves. Fitoterapia 2000, 71(2):193-194.
• [3]Misra SaD SN: Antifungal activity of leaf extract of some higher plants. Acta Botanica Indica 1979, 7:147-150.
• [4]Pal S, Nag Chaudhuri AK: Studies on the anti-ulcer activity of a Bryophyllum pinnatum leaf extract in experimental animals. J Ethnopharmacol 1991, 33(1-2):97-102.
• [5]Pal S, Nag Chaudhuri AK: Preliminary studies on the anti-inflammatory and analgesic activities of bryophyllum pinnatum (Lam.). Med Sci Res 1989, 17:561-562.
• [6]Pal S, Nag Chaudhuri AK: Further studies on the anti-inflammatory profile of the methanolic fraction of the fresh leaf extract of bryophyllum pinnatum. Fitoterapia 1992, 63:451-459.
• [7]Ojewole JAO: Antihypertensive properties of bryophyllum pinnatum (Clam; oken) leaf extracts. Am J Hypert 2002, 15(4):A34-A39.
• [8]Ojewole JA: Antinociceptive, anti-inflammatory and antidiabetic effects of Bryophyllum pinnatum (Crassulaceae) leaf aqueous extract. J Ethnopharmacol 2005, 99(1):13-19.
• [9]Umbuzeiro-Valent G, Roubicek DA, Haebisch EM: Mutagenic and antimutagenic evaluation of the juice of the leaves of Bryophyllum calycinum (Kalanchoe pinnata), a plant with antihistamine activity. Environ Mol Mutagen 1999, 33(4):325-327.
• [10]Gaind KN, Gupta RL: Flavonoid glycosides from Kalanchoe pinnata. Planta Med 1971, 20(4):368-373.
• [11]Marriage PB, Wilson DG: Analysis of the organic acids of Bryophyllum calycinum. Can J Biochem 1971, 49(3):282-296.
• [12]Muzitano MF, Falcao CA, Cruz EA, Bergonzi MC, Bilia AR, Vincieri FF, Rossi- Bergmann B, Costa SS: Oral metabolism and efficacy of Kalanchoe pinnata flavonoids in a murine model of cutaneous leishmaniasis. Planta Med 2009, 75(4):307-311.
• [13]Muzitano MF, Tinoco LW, Guette C, Kaiser CR, Rossi-Bergmann B, Costa SS: The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata. Phytochemistry 2006, 67(18):2071-2077.
• [14]Torres-Santos EC, Da Silva SA, Costa SS, Santos AP, Almeida AP, Rossi-Bergmann B: Toxicological analysis and effectiveness of oral Kalanchoe pinnata on a human case of cutaneous leishmaniasis. Phytother Res 2003, 17(7):801-803.
• [15]Muzitano MF, Cruz EA, de Almeida AP, Da Silva SA, Kaiser CR, Guette C, Rossi-Bergmann B, Costa SS: Quercitrin: an antileishmanial flavonoid glycoside from Kalanchoe pinnata. Planta Med 2006, 72(1):81-83.
• [16]Da-Silva SA, Costa SS, Rossi-Bergmann B: The anti-leishmanial effect of Kalanchoe is mediated by nitric oxide intermediates. Parasitology 1999, 118(Pt 6):575-582.
• [17]Cao H, Xia J, Xu D, Lu B, Chen G: The separation and identification of the flavonoids from the leaves of Bryophyllum pinnatum. Zhong Yao Cai 2005, 28(11):988-990.
• [18]Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006, 118(12):3030-3044.
• [19]Durst M, Gissmann L, Ikenberg H, zur Hausen H: A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983, 80(12):3812-3815.
• [20]Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H: A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 1984, 3(5):1151-1157.
• [21]zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92(9):690-698.
• [22]Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, Hsieh CY, Liaw KL, Hsing AW, Chen CJ: Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011, 103(18):1387-1396.
• [23]Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350.
• [24]Satoru Kyo DJK, Masaki Inoue, Taro Kanaya, Laimins LaimonisA: Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells. J Gen Virol 1997, 78:401-411.
• [25]Butz K, Hoppe-Seyler F: Transcriptional control of human papillomavirus (HPV) oncogene expression: composition of the HPV type 18 upstream regulatory region. J Virol 1993, 67(11):6476-6486.
• [26]Prusty BK, Das BC: Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. Int J Cancer 2005, 113(6):951-960.
• [27]Bharti AC, Shukla S, Mahata S, Hedau S, Das BC: Anti-human papillomavirus therapeutics: facts & future. Indian J Med Res 2009, 130(3):296-310.
• [28]Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA, Das BC: Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer 2011, 10:39. BioMed Central Full Text
• [29]Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, Kashyap V, Bhambhani S, Roy M, Batra S, et al.: Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol 2009, 135(12):1701-1709.
• [30]Zhengyin Yan GC: Evaluation of cytochrome P450 inhibition in human liver microsomes. In Optimization in drug discovery: in vitro methods. Edited by Zhengyin Yan GWC. Totowa, NJ: Humana press; 2004:231-244.
• [31]Yamagishi T, Haruna M, Yan XZ, Chang JJ, Lee KH: Antitumor agents, 110. Bryophyllin B, a novel potent cytotoxic bufadienolide from Bryophyllum pinnatum. J Nat Prod 1989, 52(5):1071-1079.
• [32]Emmanuel E, Obaseiki-Ebor KO, Telikepalli Hannumaiah, Mitscher Lester A, Delbert M: Shankel: Antimutagenic activity of extracts of leaves of four common edible vegetable plants in Nigeria (West Africa). Mutat Res Lett 1993, 302(2):109-117.
• [33]Eferl R, Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3(11):859-868.
• [34]el SA Arafa, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, El-Mahdy MA, Wani AA: Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res 2011, 706(1-2):28-35.
• [35]Bharti AC, Donato N, Singh S, Aggarwal BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101(3):1053-1062.
• [36]Halder B, Bhattacharya U, Mukhopadhyay S, Giri AK: Molecular mechanism of black tea polyphenols induced apoptosis in human skin cancer cells: involvement of Bax translocation and mitochondria mediated death cascade. Carcinogenesis 2008, 29(1):129-138.
• [37]El Abdellaoui S, Destandau E, Toribio A, Elfakir C, Lafosse M, Renimel I, Andre P, Cancellieri P, Landemarre L: Bioactive molecules in Kalanchoe pinnata leaves: extraction, purification, and identification. Anal Bioanal Chem 2010, 398(3):1329-1338.
• [38]Anjoo Kamboj aAKS: Bryophyllum pinnatum (Lam.) Kurz.: Phytochemical and pharmacological profile: A review. Pharmacognosy Rev 2009, 3(6):364-374.
• [39]Yamagishi T, Yan XZ, Wu RY, McPhail DR, McPhail AT, Lee KH: Structure and stereochemistry of bryophyllin-A, a novel potent cytotoxic bufadienolide orthoacetate from Bryophyllum pinnatum. Chem Pharm Bull(Tokyo) 1988, 36(4):1615-1617.
• [40]Supratman U, Fujita T, Akiyama K, Hayashi H: New insecticidal bufadienolide, bryophyllin C, from Kalanchoe pinnata. Biosci Biotechnol Biochem 2000, 64(6):1310-1312.
• [41]Supratman U, Fujita T, Akiyama K, Hayashi H, Murakami A, Sakai H, Koshimizu K, Ohigashi H: Anti-tumor promoting activity of bufadienolides from Kalanchoe pinnata and K. daigremontiana x tubiflora. Biosci Biotechnol Biochem 2001, 65(4):947-949.
• [42]Toshihiro Akihisa WCMCK, Tamura Toshitake, Matsumoto Taro: Sterols ofKalanchoe pinnata: First report of the isolation of both C-24 epimers of 24-alkyl-Δ25-sterols from a higher plant. Lipids 1991, 26(8):660-665.
• [43]Salimuzzaman Siddiqui SF, Siddiqui Bina S, Naheed Sultana: Triterpenoids and phenanthrenes from leaves of Bryophyllum pinnatum. Phytochemistry 1989, 28(9):2433-2438.
• [44]Wu PL, Hsu YL, Wu TS, Bastow KF, Lee KH: Kalanchosides A-C, new cytotoxic bufadienolides from the aerial parts of Kalanchoe gracilis. Org Lett 2006, 8(23):5207-5210.